Rhumbline Advisers Cti Biopharma Corp Transaction History

Rhumbline Advisers

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	BUY	$4.2 - $6.01 $32,466 - $46,457	7,730 Added 5.35%	152,126 $639,000
Q4 2022 Feb 14, 2023	BUY	$4.45 - $6.17 $11,040 - $15,307	2,481 Added 1.75%	144,396 $868,000
Q3 2022 Nov 10, 2022	BUY	$5.36 - $7.43 $82,442 - $114,280	15,381 Added 12.16%	141,915 $826,000
Q2 2022 Aug 11, 2022	BUY	$3.55 - $6.27 $449,195 - $793,368	126,534 New	126,534 $755,000
Q2 2019 Aug 14, 2019	SELL	$0.8 - $1.03 $51,799 - $66,691	-64,749 Closed	0 $0

Q1 2019 May 01, 2019	SELL	$0.9 - $1.37 $1,197 - $1,822	-1,330 Reduced 2.01%	64,749 $63,000
Q4 2018 Jan 31, 2019	BUY	$0.73 - $2.19 $15,059 - $45,179	20,630 Added 45.39%	66,079 $49,000
Q3 2018 Nov 07, 2018	SELL	$1.72 - $5.24 $5,590 - $17,030	-3,250 Reduced 6.67%	45,449 $98,000
Q2 2018 Aug 06, 2018	BUY	$3.81 - $5.26 $185,543 - $256,156	48,699 New	48,699 $243,000

Ticker CTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,385,000
Market Cap $1.04B
Description
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients w...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.